Introducing “Bench to Bedside With SIDP,” a new column covering everything from antimicrobial stewardship and pharmacokinetics/pharmacodynamics to mentorship, preceptorship, and more.
Similar to HIV, the colonial and postcolonial history is fundamental to the biology of this monkeypox outbreak.
Anushua Sinha, MD, discussed the findings, highlighting a 60.4% reduction in medically attended lower respiratory infections and significant decreases in RSV-related hospitalizations.
In the latest column from SIDP, the authors discuss having leaders to help navigate school and beyond.
Addressing patients with HIV who have fallen out of care, Shauna Applin, ARNP, provides clinical insights on treatment options and best practices for restarting therapy.
At MAD-ID 2025, Dakota Rorie, PharmD, highlights cost and access barriers to uptake of preferred CDI therapy.
Read more about the case of a 71-year-old man who was admitted after presenting with cold-like symptoms for 3 weeks.
To close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.
Andrew Aronsohn, MD, associate professor of Medicine, University of Chicago Medical Center, discusses the hepatitis C (HCV) screen and treat plan that looks to utilize a one visit approach to get people tested and on medication in the same patient encounter.
Due to worsening headaches and unrevealing cross-sectional imaging and ascites fluid analyses, this patient's differential evolved toward a central nervous system source.
The implementation of new College of American Pathologists rules presents an opportunity for collaboration between clinical microbiology laboratories and infectious disease pharmacists and physicians.
Presented at MAD-ID by Mohammed Al Musawa, PharmD, BCIDP, the study found lower clinical success with imipenem-cilastatin-relebactam in obese patients, raising questions about dosing strategies.
In the latest column from SIDP, clinicians discuss that along with the once-daily dosing for many indications, there are also compelling indications for twice-daily dosing.
A balance between antimicrobial stewardship and the search for multidrug-resistant organisms.
At the ASM Microbe conference, Mike Bromley, PhD, offers some insights on the importance of a One Health approach addressing the growing antifungal resistance to azoles and Aspergillus fumigatus because of the connection between crop spraying and the rise of resistance.
After Diane Shader Smith lost her daughter, Mallory, to a multidrug resistant infection, she turned her personal tragedy into a mission designed to inform people about antimicrobial resistance (AMR), and have the public coalesce around this expanding medical issue.
Patient-centered innovation amidst evolving regulations and policies is a key strategy.
Emily Ricotta, PhD, MSc outlines the importance of involving affected populations and refining data collection methods to improve early decision-making during epidemics
The Centers for Disease Control and Prevention (CDC) reports the rise in pediatric acute respiratory illnesses especially as there is a decrease in hygiene measures that were previously employed during the pandemic.
To close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.
Thumbi Ndung'u, BVM, PhD discussed the safety and partial virologic control observed in a Phase 2a trial using broadly neutralizing antibodies and vesatolimod in HIV treatment interruption.
Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.
Arbutus CEO Michael McElhaugh discussed trial results showing that a combination of imdusiran, an RNAi therapeutic, and pegylated interferon alfa-2α can achieve a functional cure in chronic hepatitis B patients.
Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the likelihood of other combination regimens for the treatment of multidrug-resistant HIV, including monoclonal antibodies.
At 7.1%, vitamin C deficiency in the US is rare. Unfortunately, identifying scurvy is complex, frustrating, and time-consuming for both patient and provider.
Sunil Parikh, MD, MPH, discusses the trial’s findings, noting no significant difference in malaria incidence (1.78 vs 1.84 cases per 100 person-weeks).
As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.